We showed that our highly tumor-selective MEK inactivator, i.e. LF-W271A/IC3-PA, has a wide range of antitumor activity, with particular efficacy in targeting tumors harboring the BRAFV600E mutation. Here, MAP2K7 is linked to neoplasm.